|
|
|
hPTH-Elisa
Immunoenzymetric assay for the in vitro quantitative measurement of human Intact Parathyroid Hormone (PTH) in serum and plasma. BL-35-E
For in
vitro diagnostic use only
I.
CLINICAL BACKGROUND A. Biological activities Human
parathyroid hormone (hPTH) is a major physiological regulator of phosphocalcic
metabolism. hPTH increases serum
calcium concentrations by its actions on kidney (enhancing tubular Ca++
reabsorption and phosphate excretion) and bone (stimulating osteoclastic
activity and bone resorption). It
indirectly affects intestinal absorption of
Ca++ by stimulating renal 1α-hydroxylation of 25
hydroxyvitamin D. The release of
PTH is controlled in a negative feedback loop by the serum concentration of Ca++. PTH
is synthesized in the chief cells of the parathyroid glands and secreted as an
84 amino acid molecule called "intact PTH", which is the main
bioactive product. This molecule
is degraded by proteolytic cleavage between amino acids 33-37 at peripheral
sites to form biologically active amino-terminal fragments and biologically
inactive carboxyl-terminal fragments. The
carboxyl-terminal fragments are cleared only by glomerular filtration, while
the bioactive intact PTH and amino-terminal fragments are also metabolically
degraded in the liver and other tissues.
The half-life of the carboxyl-terminal fragments increases dramatically
in patients with renal failure. Thus,
the measurement of intact PTH correlates best with the hormone production and
biological activity. B.
Clinical application
The measurement of intact hPTH is used to establish the diagnosis of
primary hyperparathyroidism by demonstrating elevated serum levels of
bioactive PTH. It allows
documenting the occurrence of secondary hyperparathyroidism in patients with
Vit.D deficiency, intestinal malabsorption, or renal failure.
In this last situation, the absence of interference with the inactive
carboxyl-terminal fragments is especially valuable. The specificity and high sensitivity of the assay also allows
differentiating clearly low serum PTH levels in hypoparathyroidism or in
tumor-induced hypercalcaemia. II.
PRINCIPLES OF
THE METHOD The
Bio-Line hPTH-ELISA is a solid phase Enzyme Amplified Sensitivity Immunoassay
performed on microtiterplates.
Calibrators and samples react with the capture polyclonal antibodies
(PAb, goat anti 1-34 PTH fragment) coated on microtiter well.
After incubation, the excess of antigen is removed by washing.
Then monoclonal antibodies (MAb, mouse anti 44-68 PTH fragment) labelled
with horseradish peroxidase (HRP) are added.
After an incubation period allowing the formation of a sandwich: coated
PAbs – human PTH – MAb – HRP, the microtiterplate is washed to remove
unbound enzyme labelled antibody. Bound
enzyme-labelled antibody is measured through a chromogenic reaction. Revelation solution (TMB – H2O2) is
added and incubated. The reaction
is stopped with the addition of Stop Solution and the microtiterplate is then
read at the appropriate wavelength. The
amount of substrate turnover is determined colourimetrically by measuring the
absorbance, which is proportional to the PTH concentration. A
calibration curve is plotted and PTH concentration in samples is determined by
interpolation from the calibration curve. The
use of the ELISA reader (linearity up to 3 OD units) and a sophisticated data
reduction method (polychromatic data reduction) result in a high sensitivity in
the low range and in an extended calibration range. III.
REAGENTS PROVIDED
Note:
1.
Use the zero calibrator for sample dilutions.
2. 1 pg of the
calibrator preparation is equivalent to 1 pg of a synthetic PTH (1-84) from the
Japanese Peptide Institute. IV.
SUPPLIES NOT PROVIDED The
following material is required but not provided in the kit: 1.
High quality distilled water 2.
Pipettes for delivery of: 50 μl, 200 μl, 1 ml and 3 ml (the use
of accurate pipettes with disposable plastic tips is recommended) 3.
Vortex mixer 4.
Magnetic stirrer 5.
Horizontal microtiterplate shaker capable of 700 rpm ± 100 rpm 6.
Washer for microtiterplates 7.
Microtiterplate reader capable of reading at 450 nm, 490 nm and 650 nm
(in case of polychromatic reading) or capable of reading at 450 nm and 650 nm
(monochromatic reading) 8.
Optional equipment: The ELISA-AID™ necessary to read the plate
according to polychromatic reading (see paragraph XI.A.) can be purchased from
Robert Maciels Associates, Inc. Mass. 0.2174 USA. V.
REAGENT PREPARATION a.
Calibrators
: Reconstitute the zero calibrator with 3.0 ml distilled water and other
calibrators with 2 ml distilled water. b.
Controls
: Reconstitute the controls with 1 ml distilled water. c.
Working Wash solution
: Prepare an adequate volume of Working Wash solution by adding 19 volumes of
distilled water to 1 volume of Wash Solution (20x). Use a magnetic stirrer to
homogenize. Discard unused Working Wash solution at the end of the day.
VI.
STORAGE AND
EXPIRATION DATING
OF REAGENTS §
Before opening or reconstitution, all kits components are stable until
the expiry date, indicated on the vial label, if kept at 2 to 8°C. §
Unused strips must be stored, at 2-8°C, in a sealed bag containing a
desiccant until expiration date. §
After reconstitution, calibrators, controls and incubation serum should
be frozen immediately after use and kept at –20°C for 3 months.
Avoid successive freeze thaw cycles. §
The concentrated Wash Solution is stable at room temperature until
expiration date. §
Freshly prepared Working Wash solution should be used on the same day. §
After its first use, the conjugate is stable until expiry date, if kept
in the original well-closed vial at 2 to 8°C. §
Alterations in physical appearance of kit reagents may indicate
instability or deterioration. IV.
SPECIMEN COLLECTION
AND PREPARATION §
Blood samples should be promptly separated from the blood cells. §
Serum and plasma must be kept at 2 - 8°C. §
If the test is not run within 8 hours, storage in aliquots at -20°C is
recommended. Avoid subsequent
freeze thaw cycles. §
Prior to use, all samples should be at room temperature.
It is recommended to vortex the samples before use. §
It is advisable to assay serum samples. §
Do not use haemolysed samples. VIII.
PROCEDURE A.
Handling notes
Do not use the kit or components
beyond expiry date. Do
not mix materials from different kit lots.
Bring
all the reagents to room temperature prior to use.
Thoroughly mix all reagents and samples by gentle agitation or swirling.
Perform calibrators, controls and samples in duplicate. Vertical alignment is recommended.
Use a clean plastic container to prepare the Wash Solution.
In order to avoid cross-contamination, use a clean disposable pipette tip
for the addition of each reagent and sample.
For the dispensing of the Revelation Solution and the Stop Solution avoid
pipettes with metal parts.
High precision pipettes or automated pipetting equipment will improve the
precision.
Respect the incubation times.
To avoid drift, the time between pipetting of the first calibrator and
the last sample must be limited to the time mentioned in section XIII paragraph
E (Time delay).
Prepare a calibration
curve for each run, do not use data from previous runs. Dispense
the Revelation Solution within 15 minutes following the washing of the
microtiterplate. During
incubation with Revelation Solution, avoid direct sunlight on the
microtiterplate. B.
Procedure 1. Select the required number of strips for the run. The unused strips should be resealed in the bag with a desiccant and stored at 2-8°C. 2. Secure the strips into the holding frame. 3. Pipette 50 µl of Incubation Buffer into all wells. 4. Pipette 200 µl of each Calibrator, Control and Sample into the appropriate wells. 5. Incubate for 2 hours at room temperature on a horizontal shaker set at 700 rpm ± 100 rpm. 6. Aspirate the liquid from each well. 7. Wash the plate 4 times by: § Dispensing 0.4 ml of Wash Solution into each well § Aspirating the content of each well 8. Pipette 100 µl of anti-PTH-HRP conjugate into all the wells. 9. Incubate for 1h at room temperature on a horizontal shaker set at 700 rpm ± 100 rpm. 10. Aspirate the liquid from each well. 11. Wash the plate 4 times by: § Dispensing 0.4 ml of Wash Solution into each well § Aspirating the content of each well 12. Pipette 100 µl of the chromogenic solution into each well within 15 minutes following the washing step. 13. Incubate the microtiterplate for 30 minutes at room temperature on a horizontal shaker set at 700 rpm ± 100 rpm, avoid direct sunlight. 14. Pipette 200 µl of Stop Solution into each well. 15. Read the absorbancies at 450 nm and 490 nm (reference filter 630 nm or 650 nm) within 1 hour and calculate the results as described in section XI. IX.
CALCULATION OF
RESULTS A.
Polychromatic Reading: 1.
In this case, the ELISA-AID™ software will do the data processing. 2.
The plate is first read at 450 nm against a reference filter set at 650
nm (or 630 nm). 3.
A second reading is performed at 490 nm
against the same reference filter. 4.
The ELISA-AID™ Software will drive the reader automatically and will
integrate both readings into a polychromatic model.
This technique can generate OD’s up to 10. 5.
The principle of polychromatic data processing is as follows: §
Xi = OD at 450 nm §
Yi = OD at 490 nm §
Using a standard unweighted linear regression, the parameters A & B
are calculated : Y = A*X – B §
If Xi < 3 OD units, then X calculated = Xi §
If Xi > 3 OD units, then X calculated = (Yi-B)/A §
A 4 parameter logistic curve fitting is used to build up the calibration
curve. §
The PTH concentration in samples is determined by interpolation on the
calibration curve. B.
Bichromatic Reading 1.
Read the plate at 450 nm against a reference filter set at 650 nm (or 630
nm). 2.
Calculate the mean of duplicate determinations. 3.
On semi-logarithmic or linear graph paper plot the OD values (ordinate)
for each calibrator against the corresponding concentration of PTH (abscissa)
and draw a calibration curve through the calibrator points by connecting the
plotted points with straight lines. 4.
Read the concentration for each control and sample by interpolation on
the calibration curve. 5.
Computer assisted data reduction will simplify these calculations.
If automatic result processing is used, a 4 parameter logistic function
curve fitting is recommended. X.
TYPICAL DATA The
following data are for illustration only and should never be used instead of the
real time calibration curve.
XI.
PERFORMANCE AND LIMITATIONS A.
Detection Limit Twenty
zero calibrators were assayed along with a set of other calibrators. The
detection limit, defined as the apparent concentration two standard deviations
above the average OD at zero binding, was 2 pg/ml. B.
Specificity Cross-reactive
hormones or fragments were added to the zero calibrator,
a high value calibrator (900 pg/ml) and a low value calibrator (100
pg/ml). The apparent PTH response
was measured.
C.
Precision
SD
: Standard Deviation; CV: Coefficient of variation D.
Accuracy
RECOVERY
TEST
Samples
were diluted with zero calibrator. E.
Time delay between last calibrator and sample dispensing As
shown hereafter, assay results remain accurate even when a sample is dispensed
60 minutes after the calibrators have been added to the coated wells.
XII.
INTERNAL QUALITY
CONTROL §
If the results obtained for Control 1 and/or Control 2 are not within the
range specified on the vial label, the results cannot be used unless a
satisfactory explanation for the discrepancy has been given. §
If desirable, each laboratory can make its own pools of control samples,
which should be kept frozen in aliquots. Controls
which contain azide will interfere with the enzymatic reaction and cannot be
used. §
Acceptance criteria for the difference between the duplicate results of
the samples should rely on Good Laboratory Practises §
It is recommended that Controls be routinely assayed as unknown samples
to measure assay variability. The
performance of the assay should be monitored with quality control charts of the
controls. §
It is good practise to check visually the curve fit selected by the
computer. XIII.
REFERENCE INTERVALS These
values are given only for guidance; each laboratory should establish its own
normal range of values.
The
range is based on 5% to 95% percentiles. XIV.
PRECAUTIONS AND
WARNINGS Safety For
in vitro diagnostic use only. The
human blood components included in this kit have been tested by European
approved and/or FDA approved methods and found negative for HBsAg, anti-HCV,
anti-HIV-1 and 2. No known method
can offer complete assurance that human blood derivatives will not transmit
hepatitis, AIDS or other infections. Therefore,
handling of reagents, serum or plasma specimens should be in accordance with
local safety procedures. All
animal products and derivatives have been collected from healthy animals. Bovine
components originate from countries where BSE has not been reported.
Nevertheless, components containing animal substances should be treated as
potentially infectious. Avoid
any skin contact with all reagents, Stop
Solution contains H2SO4, the chromogen contains TMB in
Dimethylformamide, Substrate buffer contains H2O2.
In case of contact, wash thoroughly with water. Do
not smoke, drink, eat or apply cosmetics in the working area.
Do not pipette by mouth. Use
protective clothing and disposable gloves.
XV.
BIBLIOGRAPHY 1.
HABENER J.F., and POTTE J.T., Jr. (1978) "Biosynthesis
of parathyroid hormone". New
Engl. J. Med., 299, 11:580 and 299, 12:635. 2.
MARTIN K.J., HRUSKA K.A., FREITAG J.J., KLAH S. and SLOTOPOLSKY E.
(1979) "The
peripheral metabolism of parathyroid hormone". New
Engl. J. Med., 301, 20:1092. 3.
GOLTZMAN D., HENDERSON B. and LOVERIDGE N.
"Cytochemical bioassay of PTH.
(1980) Characteristics
of the assay and analysis of circulating hormone forms". J.
Clin. Invest., 65:1309. 4.
POTTS J.T. Jr., KRONENBERG H.M., ROSENBLATT M.
(1982) "Parathyroid
hormone : Chemistry, biosynthesis and mode of action". Adv.
Protein Chem., 323. 5.
HACKENG W.H.L., LIPS P., NETELENBOS J.C. and LIPS C.J.M. (1986) "Clinical
implication of estimation of intact parathyroid hormone (PTH) versus total
immunoreactive PTH in normal subjects and hyperparathyroid patients". J.
Clin. Endocrinol. Metab., 63:447. 6.
BOUILLON R., COOPMANS W., DE GROOTE D.E.H., RADOUX D., ELIARD P.H.
(1990) "Immunoradiometric
assay of Parathyrin with polyclonal and monoclonal region specific
antibodies". Clin.
Chem., 36/2:271-276. XVI
SUMMARY OF THE PROTOCOL
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|